Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
Authors:
- Alfredo V. ChuaACAlfredo V. Chua
- Jennifer DelmericoJDJennifer Delmerico
- Haiyang ShengHSHaiyang Sheng
- Xin-Wei HuangXHXin-Wei Huang
- Emily LiangELEmily Liang
- Shipra GandhiSGShipra Gandhi
- Igor PuzanovIPIgor Puzanov
- Prantesh JainPJPrantesh Jain
- Lori C. SakodaLSLori C. Sakoda
- Christine B. AmbrosoneCAChristine B. Ambrosone
- 1 March 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (3) , 408-417
Abstract
PURPOSE: Minoritized racial/ethnic groups are historically under-represented in cancer clinical trials, which may be exacerbated in recent trials on immune checkpoint inhibitors (ICIs). We examined the representation and reporting of the racial/ethnic composition of participants in clinical trials on ICIs. METHODS: We examined English full-text trials on ICIs published from 2007 to 2022. Information on trial characteristics and racial/ethnic composition of participants was extracted from published papers or ClinicalTrials.gov. Differences in participation by publication year, ICI agent, and cancer site were analyzed. Enrollment-incidence ratio (EIR) was calculated to compare the proportion of minoritized racial/ethnic group patients in US-based trials against age-adjusted cancer incidence data available for the US population. An EIR > 1 signified over-representation, whereas an EIR P values ≤.05). CONCLUSION: Disparities in the representation and reporting of minoritized racial/ethnic groups persist in recent trials on ICIs, necessitating collaborative efforts for improved diversity and equitable cancer treatment access.Keywords
This publication has 29 references indexed in Scilit:
- A biopsychosocial model to understand racial disparities in the era of cancer immunotherapyTrends in Cancer, 2022
- Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor TrialsThe American Journal of Medicine, 2022
- Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical StudiesJAMA Network Open, 2021
- Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug DevelopmentJAMA Oncology, 2021
- Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studiesInternational Journal of Cancer, 2019
- Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018JAMA Oncology, 2019
- Increasing Diversity in Clinical Trials: Overcoming Critical BarriersCurrent Problems in Cardiology, 2019
- Influence of race, ethnicity and socioeconomic status on kidney diseaseNature Reviews Nephrology, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Participation in Cancer Clinical TrialsJAMA, 2004